Clinical Trials on Aneurysmal Disease of the Abdominal Aorta in Belgium

Total 340 results

Ono Pharma USA Inc

Completed

A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (DreaMS)

Multiple Sclerosis

United States, Belgium, Canada, Czech Republic, Germany, Greece, Japan, Poland, Russian Federation, Spain, Ukraine
Taiho Oncology, Inc.

Terminated

Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial (DIGEST)

Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction

Belgium, Spain, United States, Italy, Estonia, Russian Federation, Bulgaria, Hungary, Croatia, Israel, Mexico, Poland, Portugal, Romania, South Africa, Ukraine, United Kingdom, Brazil, Germany, Argentina
Genzyme, a Sanofi Company
Bayer

Completed

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

Multiple Sclerosis, Relapsing-Remitting

Netherlands, Spain, Germany, Israel, United Kingdom, Canada, Australia, United States, Italy, Argentina, Croatia, Russian Federation, Poland, Czechia, Belgium, France, Brazil, Austria, Denmark, Mexico, Serbia, Sweden, Ukraine
Centre Hospitalier Universitaire de Liege
Sanofi; Takeda; University of Liege; Orchard Therapeutics; Centre Hospitalier Régional... and other collaborators

Recruiting

Baby Detect : Genomic Newborn Screening

Congenital Adrenal Hyperplasia | Hemophilia A | Hemophilia B | Mucopolysaccharidosis I | Mucopolysaccharidosis II | Cystic Fibrosis | Alpha 1-Antitrypsin Deficiency | Sickle Cell Disease | Fanconi Anemia | Chronic Granulomatous Disease | Wilson Disease | Severe Congenital Neutropenia | Ornithine Transcarbamylase... and other conditions

Belgium
Bayer

Completed

BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose (Beyond)

Multiple Sclerosis, Relapsing-Remitting

Belgium, Israel, United States, Canada, France, Switzerland, Ireland, Italy, Australia, Spain, Austria, Germany, Brazil, Netherlands, Poland, Russian Federation, Hungary, Slovenia, Argentina, Ukraine, Greece, Sweden, Finland, Latvia, No... and more
Incyte Corporation

Active, not recruiting

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

Squamous Cell Carcinoma of the Anal Canal

United States, Italy, Spain, United Kingdom, Australia, France, Germany, Sweden, Japan, Norway, Belgium, Denmark, Puerto Rico
Novartis

Completed

Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis

Greece, Russian Federation, Switzerland, Germany, Israel, Ireland, Belgium, Finland, United Kingdom, Netherlands, Canada, Romania, Hungary, Poland, Czech Republic, Australia, Estonia, France, Slovakia, South Africa, Sweden, Turkey
Janssen Research & Development, LLC

Completed

A Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn

Erythroblastosis, Fetal | Early Onset Severe Hemolytic Disease of the Fetus and Newborn (EOS-HDFN)

United States, Canada, Netherlands, Belgium, Australia, Germany, Spain, Sweden, United Kingdom
CENTOGENE GmbH Rostock

Active, not recruiting

Epidemiological Study in FRONtoTemporal Dementia (EFRONT)

Frontotemporal Dementia

Italy, Spain, Belgium, Turkey, Portugal, Germany, Greece
Bayer

Completed

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

Multiple Sclerosis, Relapsing-Remitting

Belgium, Israel, Sweden, United States, France, Switzerland, Ireland, Canada, Australia, Brazil, Austria, Poland, Germany, Hungary, Netherlands, Russian Federation, Spain, Argentina, Slovenia, Greece, Finland, Denmark, Ukraine, Italy, L... and more
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
EMD Serono Research & Development Institute, Inc.

Terminated

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

Relapsing Multiple Sclerosis

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Colombia, Croatia, Czechia, Estonia, Finland, France, Georgia, Germany, Hong Kong, Hungary, India, Israel, Italy, Korea, Republic of, M... and more
Novartis Pharmaceuticals

Recruiting

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (ALITHIOS)

Relapsing Multiple Sclerosis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Germany, Hungary, Poland, Portugal, Russian Federation, Slovakia, Spain, Denmark, France, Japan, Israel, Taiwan, Turkey, Czechia, Argentina, Estonia, United Kingdom, India, C... and more
Hoffmann-La Roche

Completed

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

United States, United Kingdom, Australia, Belgium, Brazil, Croatia, France, Canada, Slovakia, Germany, Netherlands, Norway, Italy, Poland, Switzerland, Romania, Bulgaria, Spain, Mexico, Austria, Portugal, Turkey, Sweden, Argentina, Denmark and more
Genzyme, a Sanofi Company
Bayer

Completed

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two (CARE-MS II)

Multiple Sclerosis, Relapsing-Remitting

Australia, Denmark, Canada, United States, Netherlands, Argentina, Austria, Belgium, Brazil, Croatia, Czech Republic, France, Germany, Israel, Italy, Mexico, Poland, Russian Federation, Serbia, Spain, Sweden, Ukraine, United Kingdom
Denali Therapeutics Inc.
Takeda

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)

Frontotemporal Dementia

Spain, Turkey, France, Belgium, Netherlands, Portugal, Italy, Colombia, Czechia, Brazil, United Kingdom, Serbia
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

Relapsing Multiple Sclerosis

China, Spain, Switzerland, Taiwan, United States, Italy, Austria, Belgium, Saudi Arabia, United Arab Emirates, Latvia, Poland, Argentina, India, Croatia, Bulgaria, Malaysia, Slovakia, Israel, Lebanon, Guatemala, Netherlands, Colombia, Chil... and more
Biogen

Active, not recruiting

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (CONNECT)

Relapsing-Remitting Multiple Sclerosis

Italy, Belgium, United States, Hungary, Sweden, United Kingdom, Israel, France, Czechia, Poland, Serbia, Denmark, Spain, Turkey, Bulgaria, Germany, Canada, Kuwait
Genzyme, a Sanofi Company

Completed

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 (TOPAZ)

Relapsing Remitting Multiple Sclerosis

United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, Denmark, Germany, Israel, Italy, Mexico, Netherlands, Poland, Russian Federation, Spain, Sweden, Ukraine, United Kingdom
Biogen
Alkermes, Inc.

Completed

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

Multiple Sclerosis

United States, Bulgaria, Poland, Belgium, Canada, Germany, Russian Federation, Serbia, Spain, Ukraine
Actelion

Completed

Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Switzerland, Ukraine, United Kingdom
MedDay Pharmaceuticals SA

Terminated

Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) (SPI2)

Multiple Sclerosis

United States, Spain, Canada, Australia, United Kingdom, Belgium, Turkey, Czechia, Poland, Italy, Hungary, Germany, Sweden
argenx

Recruiting

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United Kingdom, Spain, United States, Austria, Germany, Belgium, Italy, Netherlands, France, Georgia, Poland, Canada
Biogen

Terminated

Natalizumab (Tysabri) Re-Initiation of Dosing (STRATA)

Relapsing-Remitting Multiple Sclerosis

Finland, Germany, Spain, Belgium, Italy, Canada, France, New Zealand, Israel, Hungary, Greece, Australia, Netherlands, United Kingdom, Denmark, Ireland, Sweden, Poland, Czech Republic, Switzerland, Turkey
Wave Life Sciences Ltd.

Terminated

Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) (FOCUS-C9)

ALS | FTD

Canada, Belgium, New Zealand, Netherlands, Australia, Sweden, United Kingdom, Ireland
Hoffmann-La Roche

Active, not recruiting

Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis (MuSicalE)

Multiple Sclerosis

Belgium, United Kingdom, Netherlands, Serbia, Poland, Slovakia, Bulgaria, Turkey, Brazil, Italy, Russian Federation, Spain, Austria, Colombia, Romania, Kuwait, Chile, Dominican Republic, Egypt, Montenegro, Panama, Paraguay, Portugal, ... and more
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Multiple Sclerosis

United States, Brazil, Poland, United Kingdom, Turkey, Bulgaria, Belgium, Canada, Denmark, France, Germany, Greece, Hungary, Italy, Peru, Portugal, Russian Federation, Spain, Switzerland, Ukraine, Mexico, Argentina
Biogen

Completed

A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes (PROTEC)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

France, Italy, Spain, Czechia, Hungary, Austria, Belgium, Canada, Portugal, Slovakia, Slovenia
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (O'HAND)

Multiple Sclerosis, Primary Progressive

Canada, United States, Spain, Croatia, Serbia, Portugal, France, Tunisia, Mexico, Poland, Russian Federation, Australia, Belgium, Italy, United Kingdom, Ukraine, Bulgaria, Colombia, Georgia, Germany, Romania, New Zealand, Lebanon, Aus... and more
AstraZeneca
Innate Pharma

Active, not recruiting

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (INTERLINK-1)

Squamous Cell Carcinoma of the Head and Neck

United States, France, Italy, Spain, Belgium, Canada, Taiwan, Switzerland, Korea, Republic of, Japan, Poland, Russian Federation, United Kingdom, Austria, Brazil, Germany, Netherlands, Portugal, Australia, Philippines, Bulgaria, G... and more
Grifols Therapeutics LLC

Completed

A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations

Myasthenia Gravis Exacerbations

Belgium, Poland, Canada, Argentina, Estonia, France, Hungary, Romania, Czechia, Latvia, Russian Federation, South Africa
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis (THEIA)

Giant Cell Arteritis

United States, Canada, Belgium, Israel, Italy, Germany, France, Spain, Poland
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (CONCERTO)

Multiple Sclerosis

United States, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Estonia, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Moldova, Republic of, Montenegro, North Macedonia and more
EMD Serono Research & Development Institute, Inc.

Completed

CLARITY Extension Study

Relapsing-Remitting Multiple Sclerosis

Croatia, United States, Bulgaria, France, Italy, Russian Federation, Turkey, United Kingdom, Estonia, Germany, Latvia, Lithuania, Poland, Austria, Brazil, Canada, Finland, Portugal, Greece, Serbia, Denmark, Ukraine, Saudi Arabia, Lebanon and more
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Multiple Sclerosis, Primary Progressive

United States, Canada, Australia, Hungary, Brazil, Finland, Italy, Germany, Romania, Lithuania, France, Greece, Peru, Portugal, Spain, Switzerland, Bulgaria, Ukraine, Israel, Poland, Austria, New Zealand, Netherlands, Belgium, Mexico, United... and more
Novartis Pharmaceuticals

Terminated

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS. (INFORMS)

Primary Progressive Multiple Sclerosis

United States, Belgium, Poland, Germany, Hungary, Turkey, Spain, Australia, Canada, Czechia, Switzerland, United Kingdom, Netherlands, France, Italy, Denmark, Finland, Sweden
Immunovant Sciences GmbH

Recruiting

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

Chronic Inflammatory Demyelinating Polyneuropathy

United States, Italy, Norway, Greece, Poland, Sweden, Argentina, Belgium, Denmark, Finland, Germany, Portugal, Romania, Slovakia, Spain, Bulgaria, Korea, Republic of, United Kingdom, Brazil, Serbia
Seagen Inc.
Genmab

Completed

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Bladder Cancer | Cervix Cancer | Ovary Cancer | Esophagus Cancer | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Endometrium Cancer | Prostate Cancer (CRPC) | Lung Cancer(NSCLC)

United States, Belgium, United Kingdom, Denmark, Sweden
Sanofi

Recruiting

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) (PERSEUS)

Primary Progressive Multiple Sclerosis

Spain, Italy, Turkey, India, Israel, Bulgaria, Mexico, Greece, Portugal, United States, Argentina, Australia, Austria, Belarus, Belgium, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Estonia, France, Georgia, Germany, Hungary, Japan and more
Hoffmann-La Roche
PPD

Recruiting

A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis (Operetta 2)

Relapsing-Remitting Multiple Sclerosis

United States, Belgium, Canada, Spain, India, Italy, Mexico, Portugal, Argentina, Austria, Brazil, United Kingdom, Germany, Netherlands, Serbia, Australia, Bulgaria, France, Greece, Hungary, Poland, Ukraine, Estonia, Denmark, Croatia, Latvia and more
Biogen

Completed

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis (DEFINE)

Relapsing-Remitting Multiple Sclerosis

Croatia, United States, Czech Republic, France, Italy, Mexico, South Africa, United Kingdom, Germany, Poland, Romania, Ukraine, Netherlands, Austria, Canada, Israel, New Zealand, Slovakia, Greece, Serbia, India, Belgium, Switzerland, ... and more
Transposon Therapeutics, Inc.

Active, not recruiting

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Amyotrophic Lateral Sclerosis | Frontotemporal Dementia

Spain, United States, Belgium, France, Germany
Grifols Therapeutics LLC

Completed

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Belgium, Czechia, Estonia, Canada, France, Germany, Hungary, Poland, Lithuania
Astellas Pharma Inc

Completed

Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis (SONIC)

Multiple Sclerosis | Spinal Cord Diseases | Neurogenic Bladder

Australia, France, Belgium, Germany, Netherlands, Italy, Spain, United Kingdom, Hungary, Czechia, Russian Federation
Biogen

Completed

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis (CONFIRM)

Relapsing-Remitting Multiple Sclerosis

United States, Croatia, Bulgaria, Czech Republic, France, Mexico, Poland, Spain, Germany, Belarus, Estonia, Latvia, Romania, Ukraine, Israel, New Zealand, Slovakia, Greece, India, Serbia, Ireland, Costa Rica, Canada, Belgium, Macedonia,... and more
Biogen

Completed

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)

Relapsing-Remitting Multiple Sclerosis

United States, France, Germany, Spain, Belgium, Czechia, Switzerland, United Kingdom, Austria, New Zealand, Australia, South Africa, Ukraine, Italy, Slovakia, Greece, Poland, Israel, Netherlands, Bulgaria, Serbia, India, Romania, Estonia and more
Novartis

Completed

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase (TRANSFORMS)

Multiple Sclerosis

United States, Korea, Republic of, Portugal, Canada, Hungary, Spain, Germany, United Kingdom, Australia, Argentina, Austria, Belgium, Brazil, Egypt, France, Greece, Italy, Switzerland
Incyte Corporation

Completed

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Hepatocellular Carcinoma | Colorectal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Castration Resistant Prostate Cancer | Gastric/ Gastroesophageal Junction | Squamous Carcinoma...

United States, Spain, France, United Kingdom, Italy, Belgium
argenx

Completed

Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis (ADAPTsc)

Generalized Myasthenia Gravis

Spain, United States, Belgium, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation
argenx

Active, not recruiting

An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis (ADAPT NXT)

Generalized Myasthenia Gravis

Georgia, United States, Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Spain
argenx

Active, not recruiting

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE+)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Israel, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, Spain, Ukraine, United Kingdom, Latvia, Romania, Taiwan, Turkey

Clinical Trials on Aneurysmal Disease of the Abdominal Aorta in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations